Core Viewpoint - Notai Bio (688076.SH) has been penalized for financial fraud, leading to a downgrade in valuation by fund companies after being designated as ST (Special Treatment) following its resumption of trading [2][7]. Group 1: Financial Fraud and Penalties - The China Securities Regulatory Commission (CSRC) confirmed that Notai Bio's 2021 annual report contained false records, resulting in a total fine of 76.2 million yuan for the company and several executives [2][6]. - Notai Bio's fraudulent activities included inflating revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported total profit for that year [4][5]. - The company was also penalized for providing misleading financial information in its bond issuance documents, leading to additional fines totaling 47.4 million yuan [5][6]. Group 2: Market Impact and Fund Valuation Adjustments - Following the ST designation, Notai Bio's stock closed at 44.51 yuan per share, with a total market capitalization of 14.07 billion yuan [3]. - On July 22, 2025, the valuation of Notai Bio's stock was adjusted to 32.78 yuan by the招商基金, reflecting a reduction of approximately 20% from its previous price of 40.98 yuan [8][9]. - As of the end of Q2 2025, 19 funds from 8 public fund companies held a total of 9.23 million shares of Notai Bio, with a combined market value of 344 million yuan, representing 2.93% of the total share capital [10].

Core Viewpoint - The stock of NuoTai Bio (688076.SH) was officially changed to "ST NuoTai" following the announcement of a financial fraud case, leading to an 11% drop in stock price on the first trading day after the change [1][2]. Group 1: Financial Fraud Details - NuoTai Bio's financial fraud was revealed in the "Administrative Penalty Notice" issued by the China Securities Regulatory Commission (CSRC), indicating that the company had fabricated financial data in its 2021 annual report [2][3]. - The fraudulent activity involved a technology transfer to Zhejiang Huabei Pharmaceutical Co., which lacked the financial capability and operational capacity to pay for or utilize the technology, resulting in an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, accounting for 20.64% of the reported profit [3][4]. - NuoTai Bio also included false financial data in its convertible bond issuance documents, continuing to use the fraudulent 2021 financial figures in its fundraising materials [3]. Group 2: Penalties and Consequences - The CSRC proposed penalties against NuoTai Bio, including a fine of 47.4 million yuan and warnings for the company and its executives, with total penalties amounting to 76.2 million yuan, setting a record for penalties on the STAR Market [4][5]. - The actual controllers of NuoTai Bio, Zhao Dezhong and Zhao Deyi, received fines of 13 million yuan and 5 million yuan respectively, while four senior executives were fined between 1.5 million and 3.3 million yuan [4][5]. Group 3: Role of Nanjing Securities - Nanjing Securities, the sponsor for NuoTai Bio's IPO and convertible bond issuance, is implicated in the fraud due to its confirmation of the accuracy of the financial disclosures in the listing and bond issuance documents [6]. - Nanjing Securities earned approximately 66.3854 million yuan in underwriting fees from the IPO and around 5.66 million yuan from the convertible bond project [6]. - The firm has faced multiple issues with its sponsored projects, including instances of financial fraud and information disclosure violations [7][8].

江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）的股票自2025年2月27日至4月2日期间，已 满足连续三十个交易日中至少有十五个交易日的收盘价不低于"诺泰转债"当期转股价格（42.23元/股） 的130%（含130%，即54.899元/股），根据《江苏诺泰澳赛诺生物制药股份有限公司向不特定对象发行 可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，已触发"诺泰转债"的有条件赎回 条款。 （二）本次可转债赎回事项公告披露情况 公司于2025年4月2日召开第三届董事会第二十五次会议审议通过了《关于提前赎回"诺泰转债"的议 案》，决定行使"诺泰转债"的提前赎回权，对"赎回登记日"登记在册的"诺泰转债"全部赎回。具体内容 详见公司于2025年4月3日在上海证券交易所网站（www.sse.com.cn）披露的《江苏诺泰澳赛诺生物制药 股份有限公司关于提前赎回"诺泰转债"的公告》（公告编号：2025-018）。 2025年4月17日，公司在上海证券交易所网站（www.sse.com.cn）披露了《江苏诺泰澳赛诺生物制药股 份有限公司关于实施"诺泰转债"赎回暨摘牌的公告》（公告编号：2025-022） ...

明天161124港股小盘LOF会封死跌停的，而且，后天还会封死跌停，我怀疑最后就是跌到成本附近，大家白忙活。 这让我想起个故事。 上次我去澡堂子洗澡： 牛：老板，你这儿洗澡多少钱？ 老板：男浴池10元，女浴池100元。 牛：为什么女浴池那么贵？ 老板：你就说想去男浴池还是女浴池？ 牛：一听这话，果断交了100块。 兴冲冲进女浴池一看，全是买票进来的男的。。。 被骗过一次长记性了。 但前天我去澡堂子，心里又痒痒了，我想虽然概率很低，但成本不高，万一要是能遇到个女的呢？ 最后还是忍不住买了100块钱的票。 风语转债：董事会提议下修 维尔转债：下修到底 赛力医疗：收到证监会湖北监管局行政处罚决定书 | 转债代码 | 转债名称 | 强赎天计数 | 现价 | 转股价值 | 溢价率 | 剩余规模 | 转债占正股 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | (亿元) | 流通市值比 | | 128144 | 利民转债 | 还需0天 | 145.777 | 146.35 | -0.39% | 5.042 | 11.10% | | 1136 ...

凌钢转债：下修到底 鼎龙转债：4月23日上市 | 搜 | | --- | | 索 | | 公 | | 众 | | 号 | | "jisilu8" | | 添 | | 加 | | 我 | | 们 | | 转债代码 | 转债名称 | 现价 | 强赎价 | 最后交易日 | 最后转股日 | 转股价值 | 剩余规模 | 转债占止股 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | (亿元) | 流通市值比 | | 113582 | 火炬转债 | 150.743 | 101.632 | 2025-04-17 | 2025-04-22 | 151.95 | 0.056 | 0.03% | | 123228 | 震裕转债 | 220.700 | 100.200 | 2025-04-17 | 2025-04-22 | 223.69 | 0.015 | 0.01% | | 127051 | 博杰转债 | 106.150 | 100.700 | 2025-04-24 | 2025-04-24 | 106.41 | 0.091 | 0. ...

富春转债，沪工转债，山石转债，富淼转债，芯海转债：不下修 首华转债：董事会提议下修 中环环保：股东拟减持不超过3.55%股份 *ST普利：公司重大违法退市，退市整理期2025年4月28日至2025年5月21日 预计最后交易日期为2025年5月21日，入退市整理期的首个交易日不实行价格涨跌幅限制，此后每个交易日的涨跌幅限制为 20% *ST天创：申请撤销退市风险警示，审计报告无法表示意见涉及事项影响已消除 | 转债代码 转债名称 | 现价 | 赎回价 | 最后交易日 | 最后转股日 | 转股价值 | 剩余规模 | 转债占正股 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | (税前) | | | | (亿元) | 流通市值比 | | 123099 普利转债 | 93.549 | | 2025-05-21 | 2025-05-21 | 83.00 | 2.023 | 18.14% | 关注集思录微信 特别提示 本文不构成任何投资建议，仅为信息分享。任何因本文导致的投资行为发生的亏损，本公众号及作者概不承担任何责任。 南方顺丰物流REIT【18030 ...

Group 1 - The article mentions that Zhengfan Convertible Bond will be listed on April 3 [1] - Nuotai Convertible Bond is subject to strong redemption [1] - New Hope expects a net profit of 430 million to 500 million yuan in the first quarter of 2025 [1] - Zhibang Convertible Bond will be listed on April 8 [1] - Qingyuan Co., Ltd. will have a convertible bond subscription on April 8 [1] Group 2 - The article encourages readers to follow the WeChat account of Jisilu for more information [2]